Gliclazide is a sulfonylurea that has hypoglycemic and potentially useful haemovascular properties. It stimulates the influx of calcium ions into pancreatic β-cells and as a result increases insulin secretion. Moreover, in vivo studies have demonstrated changes in thrombin-induced platelet aggregation in NIDDM patients treated with Gliclazide.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign Out
